檢索結果 - Maria Dall’Era

Refine Results
  1. 1
    Type I interferon correlates with serological and clinical manifestations of SLE

    Type I interferon correlates with serological and clinical manifestations of SLE 由 Maria Dall’Era

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome

    Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome 由 Maria Dall’Era, Victoria Levesque, Neil Solomons, Matt Truman, David Wofsy

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment

    Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment 由 Kyriakos A. Kirou, Maria Dall’Era, Cynthia Aranow, Hans‐Joachim Anders

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project

    Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project 由 Ernest Maningding, Maria Dall’Era, Laura Trupin, Louise B. Murphy, Jinoos Yazdany

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review

    Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review 由 Savino Sciascia, Massimo Radin, Jinoos Yazdany, RA Levy, Dario Roccatello, Maria Dall’Era, MJ Cuadrado

    出版 2017
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the<i>MAINTAIN Nephritis Trial</i>

    A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the<i>MAINTAIN Nephritis Trial</i> 由 Farah Tamirou, Bernard Lauwerys, Maria Dall’Era, Meggan Mackay, Brad H. Rovin, Ricard Cervera, Frédéric Houssiau

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA

    Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA 由 Christopher Collins, Maria Dall’Era, H. Kan, Cynthia Macahilig, C. Molta, V. Koscielny, David J. Chang

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence

    Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence 由 Savino Sciascia, Massimo Radin, Jinoos Yazdany, Maria G. Tektonidou, Irene Cecchi, Dario Roccatello, Maria Dall’Era

    出版 2017
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  9. 9
    Current challenges in the development of new treatments for lupus

    Current challenges in the development of new treatments for lupus 由 Maria Dall’Era, Ian N Bruce, Caroline Gordon, Susan Manzi, Janis McCaffrey, Peter E. Lipsky

    出版 2019
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  10. 10
    The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project

    The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project 由 Maria Dall’Era, Miriam G. Cisternas, Kurt P. Snipes, Lisa J. Herrinton, Caroline Gordon, Charles G. Helmick

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus

    Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in S... 由 Patricia Katz, Sofia Pedro, E. Alemao, Jinoos Yazdany, Maria Dall’Era, Laura Trupin, Stephanie Rush, Kaleb Michaud

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Brief index of lupus damage: A patient‐reported measure of damage in systemic lupus erythematosus

    Brief index of lupus damage: A patient‐reported measure of damage in systemic lupus erythematosus 由 Jinoos Yazdany, Laura Trupin, Stuart A. Gansky, Maria Dall’Era, Edward H. Yelin, Lindsey A. Criswell, Patricia Katz

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Major Depression and Adverse Patient‐Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort

    Major Depression and Adverse Patient‐Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort 由 Brett Dietz, Patricia Katz, Maria Dall’Era, Louise B. Murphy, Cristina Lanata, Laura Trupin, Lindsey A. Criswell, Jinoos Yazdany

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Impact of Limited Health Literacy on Patient‐Reported Outcomes in Systemic Lupus Erythematosus

    Impact of Limited Health Literacy on Patient‐Reported Outcomes in Systemic Lupus Erythematosus 由 Patricia Katz, Maria Dall’Era, Laura Trupin, Stephanie Rush, Louise B. Murphy, Cristina Lanata, Lindsey A. Criswell, Jinoos Yazdany

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints

    Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints 由 Salem Almaani, Udayan Bhatt, Cristina Arriens, Eloísa Bonfá, Maria Dall’Era, Frédéric Houssiau, Kenneth Kalunian, Megan Mackay, Jorge Sánchez‐Guerrero, Neil Solomons, Brad H. Rovin

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A <scp>Population‐Based</scp> Study

    Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A <scp>Population‐Based</scp> Study 由 Tiffany Taylor, Christine Anastasiou, Clairissa Ja, Stephanie Rush, Laura Trupin, Maria Dall’Era, Patricia Katz, Kamil E. Barbour, Kurt J. Greenlund, Jinoos Yazdany, Milena Gianfrancesco

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis

    Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis 由 Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg, Tamiko R. Katsumoto, Paul Brakeman, Maria Dall’Era, R. John Looney, Brad H. Rovin, Leonard L. Dragone, Paul Brunetta

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta‐Analysis of the Centers for Disease Control and Prevention National Lupus Registries

    Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta‐Analysis of the Centers for Disease Control and Prevention National Lupus Registries 由 Peter Izmirly, Hilary Parton, Lu Wang, W. Joseph McCune, S. Sam Lim, Cristina Drenkard, Elizabeth D. Ferucci, Maria Dall’Era, Caroline Gordon, Charles G. Helmick, Emily C. Somers

    出版 2021
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  19. 19
    Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries

    Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries 由 Peter Izmirly, Elizabeth D. Ferucci, Emily C. Somers, Lu Wang, S. Sam Lim, Cristina Drenkard, Maria Dall’Era, W. Joseph McCune, Caroline Gordon, Charles G. Helmick, Hilary Parton

    出版 2021
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  20. 20
    Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled Dose‐Ranging</scp> Trial

    Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <s... 由 Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sánchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy Kao, Hans Guehring, Maria Dall’Era

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: